Comparative Pharmacology
Head-to-head clinical analysis: EPICORT versus TOPICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPICORT versus TOPICORT.
EPICORT vs TOPICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epicort is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by binding to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing production of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
IV: 50 mg every 8 hours over 30 minutes.
Apply a thin film to the affected skin areas twice daily. Maximum adult dose: 50 g/week. Not for use on the face, axillae, or groin. Do not use under occlusive dressings.
None Documented
None Documented
Terminal half-life is 1.5–2 hours in adults; prolonged to 3–4 hours in severe hepatic impairment
Terminal elimination half-life: 2-4 hours for parent drug; clinical effect lasts longer due to receptor binding
Renal (70% as unchanged drug and inactive metabolites), biliary/fecal (30%)
Renal (metabolites): ~75%; Fecal: ~25%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid